Results for tag: "Ixabepilone"

Ixabepilone is a semi-synthetic epothilone B analog used in the treatment of metastatic breast cancer. It is a microtubule inhibitor, meaning it works by disrupting the cell cycle and preventing the growth and spread of cancer cells. Ixabepilone is administered intravenously and is typically used in combination with other chemotherapy drugs. It is approved for use in patients who have already been treated with other chemotherapy drugs, such as taxanes, and who have not responded to those treatments. Ixabepilone is a relatively new drug, having been approved by the US Food and Drug Administration in 2007. It is marketed by Bristol-Myers Squibb under the brand name Ixempra. It is also available in generic form. The Ixabepilone market is a small but growing one, with a focus on providing treatment options for metastatic breast cancer patients who have not responded to other treatments. It is a competitive market, with several companies offering their own versions of the drug. These include Bristol-Myers Squibb, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more